Insulet Co. (NASDAQ:PODD) shares hit a new 52-week high and low during mid-day trading on Wednesday . The stock traded as low as $89.30 and last traded at $89.07, with a volume of 134847 shares traded. The stock had previously closed at $87.82.
Several research analysts have issued reports on PODD shares. UBS raised Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday, January 8th. Raymond James raised Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Monday, January 8th. Zacks Investment Research cut Insulet from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. BidaskClub raised Insulet from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Finally, Barclays reissued an “overweight” rating and issued a $90.00 target price (up from $85.00) on shares of Insulet in a research report on Thursday, February 22nd. Seven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $76.32.
The company has a quick ratio of 5.85, a current ratio of 6.24 and a debt-to-equity ratio of 3.57. The company has a market capitalization of $5,201.81, a P/E ratio of -192.28 and a beta of 1.38.
Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The company had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. During the same period last year, the business earned ($0.16) EPS. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. equities analysts predict that Insulet Co. will post -0.29 earnings per share for the current fiscal year.
In related news, COO Shacey Petrovic sold 1,319 shares of Insulet stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total transaction of $101,312.39. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David A. Lemoine sold 641 shares of Insulet stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total value of $49,235.21. The disclosure for this sale can be found here. Insiders have sold a total of 28,800 shares of company stock worth $2,412,739 in the last three months. 3.60% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. raised its stake in Insulet by 4.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 276,930 shares of the medical instruments supplier’s stock valued at $19,109,000 after purchasing an additional 10,989 shares during the period. Swiss National Bank raised its stake in Insulet by 2.9% during the 4th quarter. Swiss National Bank now owns 98,900 shares of the medical instruments supplier’s stock valued at $6,824,000 after purchasing an additional 2,800 shares during the period. New York State Common Retirement Fund raised its stake in Insulet by 14.0% during the 3rd quarter. New York State Common Retirement Fund now owns 71,585 shares of the medical instruments supplier’s stock valued at $3,943,000 after purchasing an additional 8,785 shares during the period. California Public Employees Retirement System raised its stake in Insulet by 2.0% during the 4th quarter. California Public Employees Retirement System now owns 73,155 shares of the medical instruments supplier’s stock valued at $5,048,000 after purchasing an additional 1,411 shares during the period. Finally, MetLife Investment Advisors LLC bought a new stake in Insulet during the 4th quarter valued at approximately $1,804,000.
TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/20/insulet-podd-hits-new-12-month-high-and-low-at-89-30.html.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.